Hillsdale Investment Management Inc. maintained its stake in shares of Celgene Corporation (NASDAQ:CELG) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 900 shares of the biopharmaceutical company’s stock at the end of the second quarter. Hillsdale Investment Management Inc.’s holdings in Celgene were worth $117,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in CELG. BlackRock Inc. boosted its stake in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares during the period. Oaktop Capital Management II L.P. purchased a new position in Celgene during the second quarter worth about $271,605,000. Vanguard Group Inc. boosted its stake in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares during the period. Harbour Capital Advisors LLC boosted its stake in Celgene by 12,913.6% during the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock worth $12,222,000 after buying an additional 1,575,074 shares during the period. Finally, Investec Asset Management LTD purchased a new position in Celgene during the first quarter worth about $194,490,000. 80.17% of the stock is owned by institutional investors.

Shares of Celgene Corporation (NASDAQ CELG) opened at $102.14 on Friday. The firm has a market cap of $79,385.17, a P/E ratio of 15.76, a P/E/G ratio of 0.78 and a beta of 1.78. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 earnings per share. equities analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.

In other Celgene news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the sale, the director now owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is owned by corporate insiders.

Several research firms have recently commented on CELG. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research note on Thursday, August 10th. UBS lowered shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective for the company. in a research note on Thursday, October 26th. BMO Capital Markets lowered their price objective on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. Jefferies Group reissued a “buy” rating and issued a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Finally, BTIG Research reissued a “neutral” rating on shares of Celgene in a research note on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $139.57.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/02/celgene-corporation-celg-position-held-by-hillsdale-investment-management-inc.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.